Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides

N. J. Talley, S. F. Phillips, A. Haddad, Laurence J Miller, C. Twomey, A. R. Zinsmeister, A. Ciociola

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Antagonists of 5-hydroxytryptamine type 3 (5HT3) receptors reduce the nausea induced by cisplatinum, but the effects of these agents on 5HT3 receptors in the human gut remain to be defined. We examined the actions of one of these drugs (Glaxo GR 38032F) on small intestinal transit and mouth-to-cecum transit times in healthy man. We also quantified its effects on the release of peptide YY (PYY), neurotensin, human pancreatic polypeptide, gastrin-cholecystokinin, and motilin. Ten healthy volunteers were enrolled in a randomized, double-blind, placebo-controlled crossover study. Following a single intravenous dose of GR 38032F (0.15 mg/kg), we measured the time to appearance in plasma of sulfapyridine after injection of salicylazosulfapyridine into the duodenum. This was used as a measure of duodenocecal transit. The appearance of hydrogen in breath after ingestion of a meal containing lactulose was also correspondingly used to quantify the mouth-to-cecum transit of the "head" of the meal. Gastrointestinal hormones were assayed in plasma by specific RIAs; samples were drawn fasting (10 min after injection) and after breakfast (358 calories: 15.7 g protein, 55.4 g carbohydrate, 8.1 g fat). The postprandial integrated response and peak release of PYY was decreased by GR 38032F. There was also a trend for the peak release of neurotensin to be reduced. GR 38032F did not significantly alter small intestinal transit times or mouth-to-cecum transit times. We conclude that GR 38032F does not have a major effect on small intestinal transit in health.

Original languageEnglish (US)
Pages (from-to)1511-1515
Number of pages5
JournalDigestive Diseases and Sciences
Volume34
Issue number10
DOIs
StatePublished - Oct 1989

Fingerprint

Gastrointestinal Transit
Ondansetron
Serotonin Antagonists
Cecum
Peptides
Peptide YY
Mouth
Receptors, Serotonin, 5-HT3
Neurotensin
Meals
Sulfapyridine
Motilin
Gastrointestinal Hormones
Lactulose
Sulfasalazine
Injections
Breakfast
Cholecystokinin
Gastrins
Duodenum

Keywords

  • 5-hydroxytryptamine
  • intestinal peptides
  • motility
  • small bowel transit

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. / Talley, N. J.; Phillips, S. F.; Haddad, A.; Miller, Laurence J; Twomey, C.; Zinsmeister, A. R.; Ciociola, A.

In: Digestive Diseases and Sciences, Vol. 34, No. 10, 10.1989, p. 1511-1515.

Research output: Contribution to journalArticle

Talley, N. J. ; Phillips, S. F. ; Haddad, A. ; Miller, Laurence J ; Twomey, C. ; Zinsmeister, A. R. ; Ciociola, A. / Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. In: Digestive Diseases and Sciences. 1989 ; Vol. 34, No. 10. pp. 1511-1515.
@article{16ea7aaee23544f2b30dea1406f1ddd2,
title = "Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides",
abstract = "Antagonists of 5-hydroxytryptamine type 3 (5HT3) receptors reduce the nausea induced by cisplatinum, but the effects of these agents on 5HT3 receptors in the human gut remain to be defined. We examined the actions of one of these drugs (Glaxo GR 38032F) on small intestinal transit and mouth-to-cecum transit times in healthy man. We also quantified its effects on the release of peptide YY (PYY), neurotensin, human pancreatic polypeptide, gastrin-cholecystokinin, and motilin. Ten healthy volunteers were enrolled in a randomized, double-blind, placebo-controlled crossover study. Following a single intravenous dose of GR 38032F (0.15 mg/kg), we measured the time to appearance in plasma of sulfapyridine after injection of salicylazosulfapyridine into the duodenum. This was used as a measure of duodenocecal transit. The appearance of hydrogen in breath after ingestion of a meal containing lactulose was also correspondingly used to quantify the mouth-to-cecum transit of the {"}head{"} of the meal. Gastrointestinal hormones were assayed in plasma by specific RIAs; samples were drawn fasting (10 min after injection) and after breakfast (358 calories: 15.7 g protein, 55.4 g carbohydrate, 8.1 g fat). The postprandial integrated response and peak release of PYY was decreased by GR 38032F. There was also a trend for the peak release of neurotensin to be reduced. GR 38032F did not significantly alter small intestinal transit times or mouth-to-cecum transit times. We conclude that GR 38032F does not have a major effect on small intestinal transit in health.",
keywords = "5-hydroxytryptamine, intestinal peptides, motility, small bowel transit",
author = "Talley, {N. J.} and Phillips, {S. F.} and A. Haddad and Miller, {Laurence J} and C. Twomey and Zinsmeister, {A. R.} and A. Ciociola",
year = "1989",
month = "10",
doi = "10.1007/BF01537102",
language = "English (US)",
volume = "34",
pages = "1511--1515",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides

AU - Talley, N. J.

AU - Phillips, S. F.

AU - Haddad, A.

AU - Miller, Laurence J

AU - Twomey, C.

AU - Zinsmeister, A. R.

AU - Ciociola, A.

PY - 1989/10

Y1 - 1989/10

N2 - Antagonists of 5-hydroxytryptamine type 3 (5HT3) receptors reduce the nausea induced by cisplatinum, but the effects of these agents on 5HT3 receptors in the human gut remain to be defined. We examined the actions of one of these drugs (Glaxo GR 38032F) on small intestinal transit and mouth-to-cecum transit times in healthy man. We also quantified its effects on the release of peptide YY (PYY), neurotensin, human pancreatic polypeptide, gastrin-cholecystokinin, and motilin. Ten healthy volunteers were enrolled in a randomized, double-blind, placebo-controlled crossover study. Following a single intravenous dose of GR 38032F (0.15 mg/kg), we measured the time to appearance in plasma of sulfapyridine after injection of salicylazosulfapyridine into the duodenum. This was used as a measure of duodenocecal transit. The appearance of hydrogen in breath after ingestion of a meal containing lactulose was also correspondingly used to quantify the mouth-to-cecum transit of the "head" of the meal. Gastrointestinal hormones were assayed in plasma by specific RIAs; samples were drawn fasting (10 min after injection) and after breakfast (358 calories: 15.7 g protein, 55.4 g carbohydrate, 8.1 g fat). The postprandial integrated response and peak release of PYY was decreased by GR 38032F. There was also a trend for the peak release of neurotensin to be reduced. GR 38032F did not significantly alter small intestinal transit times or mouth-to-cecum transit times. We conclude that GR 38032F does not have a major effect on small intestinal transit in health.

AB - Antagonists of 5-hydroxytryptamine type 3 (5HT3) receptors reduce the nausea induced by cisplatinum, but the effects of these agents on 5HT3 receptors in the human gut remain to be defined. We examined the actions of one of these drugs (Glaxo GR 38032F) on small intestinal transit and mouth-to-cecum transit times in healthy man. We also quantified its effects on the release of peptide YY (PYY), neurotensin, human pancreatic polypeptide, gastrin-cholecystokinin, and motilin. Ten healthy volunteers were enrolled in a randomized, double-blind, placebo-controlled crossover study. Following a single intravenous dose of GR 38032F (0.15 mg/kg), we measured the time to appearance in plasma of sulfapyridine after injection of salicylazosulfapyridine into the duodenum. This was used as a measure of duodenocecal transit. The appearance of hydrogen in breath after ingestion of a meal containing lactulose was also correspondingly used to quantify the mouth-to-cecum transit of the "head" of the meal. Gastrointestinal hormones were assayed in plasma by specific RIAs; samples were drawn fasting (10 min after injection) and after breakfast (358 calories: 15.7 g protein, 55.4 g carbohydrate, 8.1 g fat). The postprandial integrated response and peak release of PYY was decreased by GR 38032F. There was also a trend for the peak release of neurotensin to be reduced. GR 38032F did not significantly alter small intestinal transit times or mouth-to-cecum transit times. We conclude that GR 38032F does not have a major effect on small intestinal transit in health.

KW - 5-hydroxytryptamine

KW - intestinal peptides

KW - motility

KW - small bowel transit

UR - http://www.scopus.com/inward/record.url?scp=0024474193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024474193&partnerID=8YFLogxK

U2 - 10.1007/BF01537102

DO - 10.1007/BF01537102

M3 - Article

C2 - 2529108

AN - SCOPUS:0024474193

VL - 34

SP - 1511

EP - 1515

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 10

ER -